Vicore has carried out directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share, raising gross proceeds of SEK 500 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Stockholm, 9 June 2023 – “I am delighted to welcome new investors aboard our exciting journey, and I want to express my gratitude to our existing shareholders for their continued support in this transformative financing round. This fundraise further enhances our financial position and enables us to accelerate the development of our clinical pipeline, while securing the financing for the phase 2b ANDAS trial, which was designed to be representative of a pivotal trial. If the AIR trial efficacy is repeated in the ANDAS-study, it can be regarded as significant evidence of effectiveness of our lead drug candidate in IPF.”, Carl-Johan Dalsgaard, CEO of Vicore